Cornelia Haag-Molkenteller
Chief Tech/Sci/R&D Officer chez UROVANT SCIENCES LTD.
Profil
Cornelia Haag-Molkenteller is currently the Chief Medical Officer at Urovant Sciences, Inc. and the Chief Medical Officer & Executive Vice President at Urovant Sciences Ltd.
Prior to her current positions, she worked at Allergan Ltd.
(Ireland) as Vice President-Clinical Development from 2015 to 2018 and at Schwarz BioSciences GmbH as Vice President-Clinical Program from 1988 to 2006.
She holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Postes actifs de Cornelia Haag-Molkenteller
| Sociétés | Poste | Début |
|---|---|---|
| UROVANT SCIENCES LTD. | Chief Tech/Sci/R&D Officer | 01/04/2018 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Chief Tech/Sci/R&D Officer | 01/04/2018 |
Anciens postes connus de Cornelia Haag-Molkenteller
| Sociétés | Poste | Fin |
|---|---|---|
| ALLERGAN PLC | Corporate Officer/Principal | 01/03/2018 |
| Schwarz BioSciences GmbH | Corporate Officer/Principal | 01/01/2006 |
Formation de Cornelia Haag-Molkenteller
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
| Schwarz BioSciences GmbH | |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
